Tags: asthma | treatment | new

Hope for Those With Treatment-Resistant Asthma

Friday, 25 Oct 2013 04:35 PM

  Comment  |
   Contact Us  |
|  A   A  
  Copy Shortlink
New research from Japan holds promise for a new treatment, using a common anti-psychotic drug, for asthma patients resistant to corticosteroids.
In a study published in the journal Nature Communications and reported by the Medical Express Website, researchers from the RIKEN Center for Integrative Medical Sciences and Keio University in Japan found the drug Pimozide can be used to overcome resistance to steroids in severe asthma patients.

Asthma, a chronic inflammation of the airways, can be controlled with a moderate dose of inhaled corticosteroids in most patients. But up to 10 percent of patients don’t respond well to steroids and experience uncontrolled and frequent asthma attacks.
But the new research found a type of white blood cell called natural helper (NH) cells plays a critical role in corticosteroid resistance.
The Japanese team also found that Pimozide, an approved anti-psychotic drug, that restored the effects of steroids on NH cells.
"Therefore, administration of Pimozide or related drugs would be an effective treatment in human severe asthmatic patients," the researchers concluded.


  Comment  |
   Contact Us  |
  Copy Shortlink
Around the Web
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
Retype Email:
Zip Code:
Privacy: We never share your email.
Find Your Condition
You May Also Like
Around the Web
Most Commented

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

© Newsmax Media, Inc.
All Rights Reserved